EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis

Nicha Wongjarupong iD, Malique F Delbrune, Jameel Alp, Daphne M Moutsoglou, Talia Wiggen, Ashley Benner iD, Joanne L Billings, Jordan M Dunitz, Sarah J Schwarzenberg, Baharak Moshiree, Shahnaz Sultan

PLOS One · 2025

DOI: 10.1371/journal.pone.0328015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nicha Wongjarupong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, United States of America. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Intestinal Obstruction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Institutes of Health's National Center for Advancing Translational Sciences, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal (GI) complications are the second most common disorders in persons with cystic fibrosis (PwCF). There is limited data on how having a dedicated CF-GI clinic and cystic fibrosis transmembrane conductance regulator (CFTR) modulators may affect rates of GI complications. Our aim was to assess the effect of the CF-GI clinic and CFTR modulators on GI complications with incidence of distal intestinal obstructive syndrome (DIOS).

Methods

This was a retrospective study of adult PwCF who were seen in a CF-GI clinic from 2000–2023. Comparisons were made between the numbers of admissions and emergency department (ED) visits for DIOS at three years before and after CFTR modulator use and the first CF-GI clinic visit.

Results

Of the 1,076 PwCF identified, 242 were seen in CF-GI clinic. Of this, 126 (52.1%) were female, with a median age of 40 (IQR: 30–47) years. There were 146 (60.3%) with regular use of laxatives. Of the 59 PwCF with CF-GI clinic visits for constipation, hospital admissions decreased in 16, were unchanged in 32, and increased in 11 ( p = 0.402) while ED visits decreased in 9, remained the same in 40, and increased in 10 ( p = 0.862). Of the 125 PwCF with CFTR modulator use, DIOS-related hospital admissions decreased in 15 patients, remained unchanged in 89, and increased in 21 ( p = 0.021) while ED visits were fewer in 8, unchanged in 97, and increased in 20 ( p = 0.587).

Conclusion

PwCF had high burden of constipation with a majority of patients regularly using laxatives, and almost half had a history of DIOS. CFTR modulator use and CF-GI clinic were not associated with a decrease of DIOS incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIntestinal ObstructionHumansFemaleMaleAdultRetrospective StudiesIncidenceMiddle AgedEmergency Service, HospitalLaxativesHospitalizationConstipation

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, humanLaxatives

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, United States of America.
  • Department of Medicine, Division of Gastroenterology and Hepatology, Bangkok Hospital Pattaya, Chonburi, Thailand.
  • University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America.
  • Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, United States of America.
  • Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States of America.

ORCID-Profile: Nicha Wongjarupong, Ashley Benner

Förderung

  • NCATS NIH HHS
  • National Institutes of Health's National Center for Advancing Translational Sciences
  • Cystic Fibrosis Foundation

Zitieren

APA

Wongjarupong, N., Delbrune, M. F., Alp, J., Moutsoglou, D. M., Wiggen, T., Benner, A., Billings, J. L., Dunitz, J. M., Schwarzenberg, S. J., Moshiree, B., & Sultan, S. (2025). Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis. PLOS One. https://doi.org/10.1371/journal.pone.0328015

Vancouver

Wongjarupong N, Delbrune MF, Alp J, Moutsoglou DM, Wiggen T, Benner A, et al. Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis. PLOS One. 2025. doi:10.1371/journal.pone.0328015

BibTeX
@article{Wongjarupong2025,
  author = {Wongjarupong, Nicha and Delbrune, Malique F and Alp, Jameel and Moutsoglou, Daphne M and Wiggen, Talia and Benner, Ashley and Billings, Joanne L and Dunitz, Jordan M and Schwarzenberg, Sarah J and Moshiree, Baharak and Sultan, Shahnaz},
  title = {Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328015}
}
Kostenlos starten →